However, the sustained reduction in hyperglycemia after the cessation of OA treatment is clearly independent of the lipogenic pathway in the liver because the effects on SREBP-1c, ACC, FAS and SCD-1 have all subsided. The gene discussed is SCD; the disease is Hyperglycemia.